Copy

Abbott Laboratories Inc. ABT - Options Recap:

ABT was among our targeted options plays in yesterday morning's premarket report, and the company's daily activity allowed for some solid options runs. 

We were after the ABT Weekly $122-124 Calls in the wake of Abbott's Q2 earnings drop, and thanks to a solid beat on both profits and and sales along with a lofty outlook for the remainder of the year, we saw the following multibag intraday moves from our selected target contract sets. 

ABT Weekly $122-124 Calls
$122: 1.12-2.08 (+86%)
$123: .62-1.45 (+134%)
$124: .34-.85 (+150%)

We also had some NFLX Calls from Tuesday that underwent a massive dip and rip and posted the following numbers yesterday:

NFLX Weekly $635-640 Calls
$635:
 3.17-9.50 (+227%)
$640: 2.20-7.20 (+200%)
_____

Fresh Options Ideas: 
CSX Weekly $34-36 Calls
BX Weekly $130-133 Calls
T Weekly $25.50-26.50 Calls 

 

OTC Reviews:

We've also caught a couple of runners on the OTC Markets this week that we wanted to report on. We tagged initially BTZI on Monday, and LIGA yesterday morning, and they both yielded rapid results for us.  

Bots Inc. BTZI
Initial Alert: Oct 18th
Range: .0795-.1749
Gained: +120%
_____

LIG Assets, Inc. LIGA
Initial Alert: Oct 20th
Range: .0069-.013
Gained: +88%
 

Extended Watchlist:
CBTC, GDET, BBBT, MWWC, WWDH, DWAC, HX, SESN, NXTP, JRJC, INND, BLDV, MGTI

View this email in your browser
Twitter Twitter
Facebook Facebook
Website Website
LinkedIn LinkedIn
YouTube YouTube
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Our disclaimer is to be read and fully agreed to before using our site, or joining our email list. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions, however any that may occur will be corrected as needed. BHS and its affiliates are not registered or licensed investment advisers, nor broker dealers. BHS cautions that the investments in companies profiled are commonly considered to be extremely high risk and use of any information provided is at the investor's sole risk.
 
Copyright © 2021 BlueHorseshoeStocks.com, All rights reserved.

No longer want to receive our emails? You may unsubscribe from this list at any time.